PMID: 6540179Jun 1, 1984Paper

Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity

European Journal of Cancer & Clinical Oncology
R ColemanR Rubens

Abstract

Thirty-four patients with advanced breast cancer, who had not received previous chemotherapy for metastatic disease, were treated with mitoxantrone 14 mg/m2 i.v. every 21 days. Eleven of 33 evaluable patients (33%) achieved a partial response; there were no complete responders. Before commencing mitoxantrone, and 3-monthly thereafter, radionuclide assessment of ventricular performance was obtained at rest and in response to stress. Ten patients showed a deterioration in ejection fraction, two of whom developed congestive cardiac failure. Dose-limiting toxicity was myelosuppression. Nausea and vomiting were generally mild and transient. Alopecia was minimal in most patients. Mitoxantrone is an active, well-tolerated new drug in the treatment of advanced breast cancer, but cardiotoxicity may occur in a proportion of patients. Further investigation is required to determine the precise nature, incidence and prognosis of cardiotoxicity encountered with mitoxantrone.

References

Feb 1, 1976·The Journal of Pharmacy and Pharmacology·J C Double, J R Brown
Feb 8, 1979·The New England Journal of Medicine·I C Henderson, T E Frei
Nov 1, 1983·European Journal of Cancer & Clinical Oncology·R SteinerR D Rubens
Mar 1, 1980·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R D RubensJ L Hayward

❮ Previous
Next ❯

Citations

Jan 1, 1989·Cancer Chemotherapy and Pharmacology·R ColemanP Harper
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·S M O'ReillyR D Rubens
Aug 2, 2013·Chemical Research in Toxicology·Vera Marisa CostaFernando Remião
Sep 7, 2014·Mayo Clinic Proceedings·Joerg HerrmannManish Kohli
Mar 1, 1988·European Journal of Cancer & Clinical Oncology·J Carmo-PereiraA Sales-Luis
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P HeraitR Bugat
Sep 1, 1992·The British Journal of Radiology·M V MerrickR C Leonard
May 1, 1988·European Journal of Cancer & Clinical Oncology·J CassidyR C Leonard
Sep 1, 2000·Bone Marrow Transplantation·L E DamonC A Linker
May 2, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·V B Pai, M C Nahata
Aug 13, 1999·Breast Cancer Research and Treatment·M CristofanilliG N Hortobagyi
Feb 1, 1986·Drug Intelligence & Clinical Pharmacy·T I Poirier

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.